Ionpath Overview
- Founded
-
2014
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$120M
- Investors
-
14
Ionpath General Information
Description
Developer of an ion beam imaging technology designed to offer tissue imaging and analysis to accelerate discovery and improve human health. The company's technology offers a deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis, enabling health care providers to provide a diagnosis of cancer through proper actionable insights.
Contact Information
Website
www.ionpath.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
- 960 O'Brien Drive
- Menlo Park, CA 94025
- United States
+1 (833) 000-0000
Ionpath Timeline
Ionpath Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 11-May-2022 | $120M | 00000 | 00000 | Completed | Generating Revenue |
| 4. Later Stage VC (Series B) | 24-Sep-2020 | 0000 | 0000 | 0000 | Completed | Generating Revenue |
| 3. Debt - PPP | 14-Apr-2020 | 00.000 | 0000 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 01-Jul-2019 | $30.4M | $33M | 000.00 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A1) | $2.6M | $2.6M | 00.00 | Completed | Startup |
Ionpath Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series NV C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series Voting C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 | |
| Series A-1 | 1,582,839 | $0.000100 | $1.65 | $1.65 | 1x | $1.13 | 1.52% | |
| Series A | 5,006,300 | $0.000100 | $3.58 | $3.58 | 1x | $1.73 | 6.77% |
Ionpath Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an ion beam imaging technology designed to offer tissue imaging and analysis to accelerate discovery and im
Diagnostic Equipment
Menlo Park, CA
50
As of 2022
00000
0000
0000-00-00
00000000000
00000
0-0000
n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
0000000000000
Shilat, Israel
00
As of 0000
0000
0000000000 0
0000
000000
la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt moll
00000 0000000000 0000000000 0000000
Ann Arbor, MI
000
As of 0000
0000
0000
0000-00-00
000000&0
0000
Add Comparison
Ionpath Competitors (18)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| P-Cure | Venture Capital-Backed | Shilat, Israel | 00 | 0000 | 0000000000 0 | 0000 |
| 0000000 000000000 | Formerly VC-backed | Ann Arbor, MI | 000 | 0000 | 000000&0 | 0000 |
| 0000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 00 00000000 | Venture Capital-Backed | Livermore, CA | 00 | 00.000 | 000000000 | 00.000 |
| 000 0000000 000000 | Formerly PE-Backed | Melbourne, FL | 000 | 000000000000 |
Ionpath Patents
Ionpath Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200215198-A1 | Compositions and reagents for ion beam imaging | Pending | 03-Jan-2019 | 000000000 | 0 |
| JP-2022517193-A | Compositions and reagents for ion beam imaging | Pending | 03-Jan-2019 | 0000000000 | |
| EP-3906414-A1 | Compositions and reagents for ion beam imaging | Pending | 03-Jan-2019 | 000000000 | |
| EP-3759498-A1 | Source-detector synchronization in multiplexed secondary ion mass spectrometry | Active | 28-Feb-2018 | 0000000000 | |
| US-20190267227-A1 | Source-detector synchronization in multiplexed secondary ion mass spectrometry | Active | 28-Feb-2018 | H01J49/403 |
Ionpath Executive Team (8)
Ionpath Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aaron Sandoski | Norwich Ventures | Board Observer | 000 0000 |
| Frank Lee Ph.D | Self | Board Member | 000 0000 |
| Jenny Rooke Ph.D | Self | Board Observer | 000 0000 |
| Michael Angelo Ph.D | Ionpath | Co-Founder & Board Member | 000 0000 |
| Michael Dybbs Ph.D | Self | Board Member | 000 0000 |
Ionpath Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ionpath Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Thermo Fisher Scientific | Corporation | Minority | 000 0000 | 000000 0 | |
| Bruker | Corporation | Minority | 000 0000 | 000000 0 | |
| DragonScale Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| ND Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Norwich Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |